Summit Therapeutics (SMMT) Capital Expenditures (2019 - 2026)
Summit Therapeutics (SMMT) reported Capital Expenditures of $746000.0 for Q1 2026, up 76.78% on a YoY basis from $422000.0 in Q1 2025, and up 354.88% quarter-over-quarter from $164000.0 in Q4 2025.
Summit Therapeutics (SMMT) Capital Expenditures (2019 - 2026) Analysis & Trends
Summit Therapeutics has reported Capital Expenditures for 8 years, with the latest figure at $746000.0 in Q1 2026.
- For the quarter ending Q1 2026, Capital Expenditures rose 76.78% year-over-year to $746000.0; the trailing twelve-month figure through Mar 2026 stood at $981000.0 (up 76.12% YoY), and the FY2025 full-year result was $657000.0, up 372.66% from the prior year.
- Capital Expenditures for Q1 2026 stood at $746000.0, up from $164000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $746000.0 in Q1 2026, with the low at -$350000.0 in Q2 2025.
- Historically, Capital Expenditures has averaged $134941.2 across 5 years, with a median of $53000.0 in 2023.
- The largest YoY upside for Capital Expenditures was 10450.0% in 2025 against a maximum downside of 655.56% in 2025.
- Summit Therapeutics' Capital Expenditures stood at -$10000.0 in 2022, then jumped by 120.0% to $2000.0 in 2023, then soared by 6850.0% to $139000.0 in 2024, then increased by 17.99% to $164000.0 in 2025, then jumped by 354.88% to $746000.0 in 2026.
- The last three Capital Expenditures figures came in at $746000.0 (Q1 2026), $164000.0 (Q4 2025), and $421000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -63,220.27 |
| 10 | Summit Therapeutics | 10.09 Bn | 9.99 Bn | - | 746,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 746,000.00 |
| Mar 31, 2026 | 746,000.00 |
| Dec 31, 2025 | 164,000.00 |
| Dec 31, 2025 | 164,000.00 |
| Sep 30, 2025 | 421,000.00 |
| Sep 30, 2025 | 421,000.00 |
| Jun 30, 2025 | -350,000.00 |
| Jun 30, 2025 | -350,000.00 |
| Mar 31, 2025 | 422,000.00 |
| Mar 31, 2025 | 422,000.00 |
| Dec 31, 2024 | 139,000.00 |
| Dec 31, 2024 | 139,000.00 |
| Sep 30, 2024 | -67,000.00 |
| Sep 30, 2024 | -67,000.00 |
| Jun 30, 2024 | 63,000.00 |
| Jun 30, 2024 | 63,000.00 |
| Mar 31, 2024 | 4,000.00 |
| Mar 31, 2024 | 4,000.00 |
| Dec 31, 2023 | 2,000.00 |
| Dec 31, 2023 | 2,000.00 |